Navigation Links
BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
Date:8/13/2008

two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide (MBP8298), in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that MBP8298 will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4

Related biology technology :

1. BioMS Medical Announces Second Quarter 2008 Results
2. BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
3. BioMS Medical to present at BMO Healthcare Conference
4. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
5. BioMS Medical to present at Jefferies Healthcare Conference
6. BioMS Medical to present at 2008 BIO International Convention
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medical announces first quarter 2008 results
9. BioMs Medical to present at TIDES(R) Conference
10. BioMS Medical to present at Rodman and Renshaw Global Healthcare Conference
11. BioMS Medical Provides Update On Pipeline Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... 2013 In support of Swiss contributions ... General of Switzerland in New York is pleased to ... Tûranor PlanetSolar , to Manhattan. PlanetSolar is in ... 2013 tour with scientists on board from the University ... runs exclusively on energy from the sun and eliminates ...
(Date:6/18/2013)... 2013 Demanding industrial and environmental conditions ... synthetic Sapphire and Glass Ball Lenses, now available in ... Jewel Company , of Philadelphia , PA. , Optical ... the light beams without the need for direct physical ... durability (9 mohs) make it the ideal choice for ...
(Date:6/18/2013)... Nasseo, Inc. today announces that it has ... hundreds of applicants by the Arizona Commerce Authority ... . The Arizona Innovation Challenge (AIC) awards the most ... granting a financial award to what it deems to ... of the art dental and orthopedic implant surface modification ...
(Date:6/18/2013)... ATLANTA , June 18, 2013  regulated information ... Jeff Klauk today announced the launch of ... their loved ones. The Pledge ... take a stand and make a personal commitment to ... with their health care team and additional partial-onset seizure ...
Breaking Biology Technology:Switzerland’s MS Tûranor PlanetSolar, the World’s Largest Solar Boat, Arrives in New York City 2Switzerland’s MS Tûranor PlanetSolar, the World’s Largest Solar Boat, Arrives in New York City 3Switzerland’s MS Tûranor PlanetSolar, the World’s Largest Solar Boat, Arrives in New York City 4Swiss Jewel Introduces the Crown Jewels of Fiber-Optic Connectors 2Nasseo Named 2013 Innovation Challenge Winner by Arizona Commerce Authority 2Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 2Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 3Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 4Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 5Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 6
... LA JOLLA, Calif., Nov. 25 TorreyPines Therapeutics, Inc.,(Nasdaq: ... purchased from Eli Lilly & Company,a reduction in certain ... on,net sales of TorreyPines, clinical-stage compounds NGX426 and tezampanel,should ... tier,royalty rate will be reduced three percentage points and ...
... 25 t2cure, a,biopharmaceutical company developing regenerative medicine ... that it has acquired a family of,patents and ... Frankfurt University. , ... for the rapid characterization,of the potency of bone ...
... FRANCISCO, Calif., Nov. 25 Sunesis Pharmaceuticals, Inc. (Nasdaq: ... of new oncology therapeutics for the treatment of solid and hematologic ... following upcoming conferences during the month of December: , ... Annual Health Care Conference , The New ...
Cached Biology Technology:TorreyPines Therapeutics Enters into Agreement to Reduce Royalty Rates and Delay Clinical Milestone Payments Due to Eli Lilly for NGX426 and Tezampanel 2t2cure Acquires Patent Family on In Vitro Potency Testing of Stem Cells for Cardiovascular Application 2Sunesis to Present at Upcoming Conferences 2
(Date:6/18/2013)... is estimated that between 5% and 10% of breast ... to say that these tumours are attributable to inherited ... or BRCA2. In patients with these mutations, PARP inhibitors, ... results that make them a new option for personalised ... latest studies indicate that a fraction of these patients ...
(Date:6/18/2013)... June 2013). A team of internationally recognized feline experts ... Ellis from the University of Lincoln, U.K. and Dr ... were invited by the International Society of Feline Medicine ... to compile guidelines for veterinarians, owners and those working ... of the domestic cat. The new guidelines appear in ...
(Date:6/17/2013)... high levels of air pollution while pregnant were up to ... women who lived in areas with low pollution, according to ... It is the first large national study to examine links ... findings raise concerns since, depending on the pollutant, 20% to ... where risk of autism was elevated," said lead author Andrea ...
Breaking Biology News(10 mins):An article in 'Cell' reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer 2Feline behavior experts release guidelines to improve the welfare of cats 2Exposure to high pollution levels during pregnancy may increase risk of having child with autism 2
... 2008) The U.S. Environmental Protection Agency has released ... of climate change on estuaries, forests, wetlands, coral reefs, ... of Adaptation Options for Climate-Sensitive Ecosystems and Resources, identifies ... "People always say ,Don,t just tell us what ...
... a scientist from The University of Western Ontario provides ... as fact. Since renowned British biologist Richard ... ,selfish gene, in 1976, scientists the world over have ... work of Charles Darwin. In studying genomes, ...
... specialist in neural tissue engineering, has been awarded a ... Science Foundation (NSF). Pfister, who is an ... of Engineering, received the award to support and expand ... for regenerating damaged or diseased nerve cells. In ...
Cached Biology News:New report available on ecosystems and climate change 2NJIT biomedical engineer receives NSF Career Development Award 2
... Resistant SpeedVac Model SPD131DDA , Our most ... is designed to handle the rigors and solvents ... design, digital display, dual independent timers, an automatic ... and vapor pathway. , , Adjustable Vacuum ...
...
For absolute protein quantification. 4 peptides in 5 vials x 2 nmol per peptide...
The PxE Thermal Cycler (PxE) is a licensed 96 well PCR machine, developed to provide all fundamental features for value for money thermal cycling....
Biology Products: